Mark Dodson Email & Phone Number

Biographical Sketch Mark joined the CDx group at Ventana Medical Systems in 2017 and participates in the development process for new companion diagnostics. Prior to joining Ventana he served as the Scientific Advisor for Bioxiness Pharmaceuticals, which focused on anti-infective drug discovery.
Mark joined Sanofi U. S. at its Tucson Research site as a contractor in 2002 and became a company associate in 2003 and a a principal research investigator in 2007. During his time at Sanofi he worked on various small molecule drug discovery efforts in the areas of oncology, infectious diseases, metabolic disorders, and cardiomyopathies. Prior to joining Sanofi, Mark was an assistant professor in the Department of Biochemistry at the University of Arizona College of Medicine. While at the University of Arizona, his research team investigated the enzymology of herpes virus DNA replication, and he taught biochemistry and molecular genetics to undergraduate, graduate, and medical students. 

Mark received B.S. and M.A. degrees in microbiology and biology from California State University, where he worked with Jerrome Mangan in collaboration with Stanley Watson (Woods Hole Oceanographic Institution) in characterizing the molecular taxonomy of ammonia-oxidizing bacteria. He received his Ph.D. in molecular biology from The University of California, Berkeley under Harrison Echols, where he studied the mechanisms by which DNA replication origin-binding proteins function in initiating DNA replication in SV40 virus and bacteriophage lambda. Mark pursued his postdoctoral work at Memorial Sloan-Kettering Cancer Center in the laboratory of Jerard Hurwitz, where he further characterized the mechanism of SV40 virus DNA replication prior to joining the laboratory of I. R. Lehman at Stanford. While at Stanford, Mark cloned, purified and characterized several protein factors encoded by herpes simplex virus and characterized their activities. His work on these enzymes enabled the pharmaceutical industry to develop a novel class of inhibitors that target the viral DNA helicase.Mark has authored or co-authored 23 scientific articles and is a co-inventor on two U.S. patent applications.

Listed skills include Chromatography, High Throughput Screening, Methods Development, Biology, and 25 others.